GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum
GenMark Diagnostics, Inc. (NASDAQ: GNMK) will participate in the Canaccord Virtual MedTech & Diagnostics Forum on November 19, 2020, at 2:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GenMark Diagnostics, Inc. (NASDAQ: GNMK) will participate in the Canaccord Virtual MedTech & Diagnostics Forum on November 19, 2020, at 2:00 p.m. ET. The event will be accessible via live and archived webcasts at ir.genmarkdx.com.
GenMark specializes in automated multiplex molecular diagnostic testing systems, aiming to enhance patient care and reduce costs. Their eSensor XT-8® and ePlex® systems provide efficient solutions for a variety of infectious disease tests. For additional details, visit www.genmarkdx.com.
Details
News Market Reaction – GNMK
The recorded move for GNMK in the trading session of this news was +0.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTech & Diagnostics Forum.
GenMark’s management team is scheduled to present in a virtual setting on Thursday, November 19th, 2020 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com.
ABOUT GENMARK
GenMark is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Leigh Salvo
(415) 937-5404
ir@genmarkdx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.